Amgen Q4 non-GAAP EPS $4.36, up 26% YoY; full-year revenue $26.0B (+2%)

AMGEN INC

2021-FY EPS reported $10.28 revenue$25,979,000,000

Q4 total revenues $6.8B (+3% YoY); product sales -1% but volumes up for Prolia, Repatha, MVASI, EVENITY.
GAAP EPS $3.36 (+22% Q4); full-year GAAP EPS $10.28 (-16%) due to $1.5B Five Prime IPR&D write-off.
Non-GAAP EPS $4.36 Q4 (+26%), full-year $17.10 (+6%); non-GAAP operating margin 51.1%.
Full-year free cash flow $8.4B, down from $9.9B due to 2020 swap monetization and capex timing.
Quarterly dividend raised to $1.76/share, up 10% YoY (full-year $7.04, +10%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.